In cooperation with


Osteoporosis in the context of current German guidelines

Recent analysis have again proven osteoporosis as major issue for individual patients as well as to health economic aspects. The BEST-study revealed 6.3 million diagnosed patients in Germany. Osteoporosis should be diagnosed as a combination of anamnesis, clinical aspects, basic lab results and further technical assessment. Clinical diagnosis is based on DXA-bone densitometry. Recent update of current German guidelines include specific diseases and medications into risk assessment. The aim of prevention and treamtent of osteoporosis is prevention of fractures. Profound knowledge of metabolic processes should be the basis of antiosteoporotic medical treatment. Osteoblasts and osteoclasts form the smallest functional unit on cellular level. These are adressed by several treatment options. Today best evidence is avaible for estrogens, bisphosphonates (Alendronate, Risedronate, Ibandronate, Zoledronate), Raloxifene, Strontium ranelate und Teriparatide and parathyroid hormone 1-84. In 2010 Denosumab was introduced, a new potent antiresorptive acting as antibody against RANK-L. The emerging evidence in bone biology leads to developement of a bunch of new treatment options.

CME Prakt Fortbild Gynakol Geburtsmed Gynakol Endokrinol 2012; 8(2): 88–102

Osteoporosis, menopause, fracture risk, prevention, treatment

Volker Ziller, May Ziller
Klinik für Gynäkologie, gynäkologische Endokrinologie und
Onkologie, Universitätsklinikum Gießen und Marburg, Marburg

Reviewer: Isolde Frieling, Hamburg,
und Stephan Scharla, Bad Reichenhall

Ziller V. Osteoporose ... Gynakol Geburtsmed Gynakol Endokrinol 2012; 8(2): 88–102 publiziert 31.07.2012 ©akademos Wissenschaftsverlag 2012 ISSN 1614-8533